CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices (Myval or Myval Octacor) were able to meet noninferiority with respect to ...

Perspective from B. Hadley Wilson, MD, FACC CHICAGO — Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred similar rates ...

All patients had moderate to severe symptomatic aortic regurgitation and underwent TAVR with the Trilogy valve. To date, about 360 patients have at least one year of follow-up after their ...